- Home
- MFA vs SPRY Comparison
MFA vs SPRY Comparison
Compare MFA & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFA
- SPRY
- Stock Information
- Founded
- MFA 1997
- SPRY 2015
- Country
- MFA United States
- SPRY United States
- Employees
- MFA N/A
- SPRY N/A
- Industry
- MFA Real Estate Investment Trusts
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- MFA Real Estate
- SPRY Health Care
- Exchange
- MFA Nasdaq
- SPRY Nasdaq
- Market Cap
- MFA 980.3M
- SPRY 1.6B
- IPO Year
- MFA N/A
- SPRY N/A
- Fundamental
- Price
- MFA $9.36
- SPRY $17.69
- Analyst Decision
- MFA Buy
- SPRY Strong Buy
- Analyst Count
- MFA 8
- SPRY 4
- Target Price
- MFA $11.86
- SPRY $28.75
- AVG Volume (30 Days)
- MFA 1.5M
- SPRY 1.6M
- Earning Date
- MFA 08-06-2025
- SPRY 08-05-2025
- Dividend Yield
- MFA 15.38%
- SPRY N/A
- EPS Growth
- MFA N/A
- SPRY N/A
- EPS
- MFA 0.99
- SPRY N/A
- Revenue
- MFA $292,245,000.00
- SPRY $97,122,000.00
- Revenue This Year
- MFA N/A
- SPRY N/A
- Revenue Next Year
- MFA $14.73
- SPRY $170.64
- P/E Ratio
- MFA $9.45
- SPRY N/A
- Revenue Growth
- MFA 52.95
- SPRY 971120.00
- 52 Week Low
- MFA $7.85
- SPRY $8.91
- 52 Week High
- MFA $13.45
- SPRY $18.90
- Technical
- Relative Strength Index (RSI)
- MFA 42.80
- SPRY 60.97
- Support Level
- MFA $9.51
- SPRY $16.40
- Resistance Level
- MFA $9.73
- SPRY $18.05
- Average True Range (ATR)
- MFA 0.19
- SPRY 1.06
- MACD
- MFA -0.02
- SPRY 0.03
- Stochastic Oscillator
- MFA 17.27
- SPRY 62.54
About MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.